Artemisia annua (Sweet Wormwood) Benefits

Artemisia annua — sweet wormwood, sweet Annie, and for at least sixteen centuries in China qinghao (青蒿) — is the plant that gave the world artemisinin, the single most valuable antimalarial molecule ever found. In 2015 the Chinese pharmaceutical chemist Tu Youyou received the Nobel Prize in Physiology or Medicine for isolating it. Her decisive clue came from a fourth-century emergency handbook by the physician Ge Hong, the Zhouhou Beiji Fang, which said to steep the herb in cold water and wring out the juice rather than boil it. That instruction mattered because heat degrades artemisinin. It is the finest ethnobotany-to-medicine story in modern pharmacology, and we tell it properly on the malaria page.

Then comes the hard part, and it has to come early. Artemisinin-based combination therapy (ACT) is the World Health Organization’s standard of care for falciparum malaria. Artemisinin on its own is not, and the whole-herb tea is not. WHO has explicitly discouraged the use of A. annua plant material — teas, infusions, capsules, dried-leaf tablets — to treat or prevent malaria, because the low and wildly variable doses these deliver are exactly the conditions that breed artemisinin resistance. That resistance is no longer hypothetical: it is established in Southeast Asia and has since been documented in East Africa. This is one of the rare cases in herbal medicine where taking the plant instead of the drug can harm people who never touched it. We say so plainly on every page below.

Anyone with suspected malaria needs a blood test and a proper course of ACT, urgently. Malaria kills. Everything on this hub is written on that footing.

Table of Contents

1. Deep-Dive Articles
2. The Warning That Comes First
3. What the Plant Actually Contains
4. Evidence Map: Strong, Preclinical, and Absent
5. The Cold-Water Clue and the 2015 Nobel Prize
6. Cautions in Brief
7. Key Research Papers
8. External Resources
9. Connections

Deep-Dive Articles

Four articles cover this plant in depth. Start with malaria — it is the only place the evidence is genuinely strong, and it sets the honesty standard for everything else.

The Warning That Comes First

Most herb pages put safety at the bottom. This one cannot, because the risk here is not mainly to the person taking the herb.

Malaria parasites evolve. Every antimalarial that has ever been used as a single agent at a sloppy dose — quinine, chloroquine, sulfadoxine-pyrimethamine, mefloquine — has eventually been defeated. Artemisinin is the last drug class in wide use that still reliably works, and the entire global strategy for protecting it rests on two rules: always pair it with a partner drug, and always give a full, correct dose. A homemade infusion of Artemisia annua breaks both rules at once. It is single-agent artemisinin at a dose that changes with the cultivar, the soil, the harvest date, the water temperature and the steeping time.

The numbers are not a guess. In a controlled pharmacokinetic study, fourteen healthy volunteers each drank one litre of tea made from 9 g of dried A. annua leaves. That litre contained 94.5 mg of artemisinin — about 19 percent of the usually recommended daily dose. The authors were blunt: plasma levels were high enough to have a clinical effect, but not high enough to recommend such preparations as substitutes for modern artemisinin drugs. A partial dose of the one drug that still works is the worst of both worlds. It can knock the parasite count down far enough that a person feels better, then let survivors rebound — and the survivors are, by definition, the ones that tolerated artemisinin best.

The clinical picture matches. A randomised, double-blind trial in Tanzanian adults compared A. annua tea against sulfadoxine-pyrimethamine for uncomplicated falciparum malaria. Both arms looked acceptable at day 7. By day 28 the cure rate in the tea arm was 1 of 9 patients. That is not a treatment; that is a delay.

And people are already being harmed by the alternative story. French infectious-disease services published a series of travellers who developed imported Plasmodium falciparum malaria after relying on non-pharmaceutical Artemisia annua preparations for prophylaxis instead of proper chemoprophylaxis. Falciparum malaria in a non-immune traveller can go from headache to cerebral malaria in a couple of days.

None of this diminishes the plant. It sharpens what the plant deserves credit for: it handed humanity a molecule. The molecule, purified and correctly dosed and correctly paired, is a triumph. The tea is not the molecule.

What the Plant Actually Contains

Artemisia annua L. is an annual in the Asteraceae — the daisy, ragweed and chrysanthemum family — native to temperate Asia and now naturalised almost everywhere. It grows fast into a feathery, fern-leaved bush that smells sweet and resinous when crushed, which is where “sweet wormwood” and “sweet Annie” come from. It is a different plant from common wormwood (A. absinthium, the bitter thujone plant of absinthe) and from mugwort (A. vulgaris). Neither of those contains artemisinin.

• Artemisinin — a sesquiterpene lactone carrying an endoperoxide bridge, an unusual and fragile “–O–O–” link. That bridge is the whole story: it is what iron cleaves, and cleaving it releases the free radicals that kill the parasite. Content in dried leaf is typically a fraction of one percent up to roughly 1–2 percent in bred high-yield cultivars, and it varies severalfold with genetics, climate and harvest timing.
• Other sesquiterpenes — artemisinic acid, dihydroartemisinic acid (biosynthetic precursors), arteannuin B, artemisitene.
• Flavonoids — casticin, chrysosplenol D, artemetin, eupatorin and others. These have been proposed to enhance artemisinin’s activity and to slow its metabolism, which is the pharmacological core of the “whole plant is better” argument.
• Essential oil — camphor, 1,8-cineole, artemisia ketone, germacrene D and pinenes, responsible for the smell and for the plant’s antimicrobial activity in laboratory assays.
• Coumarins, phenolic acids and polysaccharides — the ordinary chemistry of a green leafy plant, and the source of routine test-tube antioxidant readings that mean very little clinically.

Artemisinin is poorly water-soluble and poorly absorbed, and the body clears it quickly — and it induces its own metabolism through the liver enzyme CYP2B6, so blood levels fall over consecutive days of dosing. Those three facts are precisely why pharmaceutical chemists built the semisynthetic derivatives (artesunate, artemether, dihydroartemisinin) rather than shipping the raw compound.

Evidence Map: Strong, Preclinical, and Absent

An honest one-screen summary of everything the four deep-dive articles cover.

The Cold-Water Clue and the 2015 Nobel Prize

In 1967 the Chinese government launched Project 523, a secret military research programme to find new antimalarials — chloroquine was failing and malaria was destroying armies in Southeast Asia. Tu Youyou, a researcher at the Academy of Traditional Chinese Medicine in Beijing, was assigned to comb the classical literature. Her team screened more than two thousand traditional recipes. Qinghao came up repeatedly for intermittent fevers, but the extracts kept failing.

The breakthrough was textual. In Ge Hong’s Zhouhou Beiji Fang (A Handbook of Prescriptions for Emergencies, circa 340 CE), the instruction was not to decoct the herb but to take a handful, soak it in about two litres of water, wring out the juice, and drink it. Tu recognised what that implied: the active principle was being destroyed by heat. Her team switched to a low-temperature ether extraction, and in 1972 obtained a crystalline compound — qinghaosu, artemisinin — with 100 percent activity against parasitaemia in mice and monkeys.

It took decades for the discovery to reach the world, and Tu Youyou shared the 2015 Nobel Prize in Physiology or Medicine for it — the first Chinese woman to win a science Nobel, and a scientist with no doctorate, no overseas training and no membership of the Chinese Academy of Sciences. The full story, including how the derivatives were engineered and why the drug is always given in combination, is on the Artemisinin and Malaria page.

One thing worth noticing: the tradition pointed at the right plant and the right extraction temperature. It did not supply a dose, a purity standard or a partner drug. Those had to be built. That gap is the entire subject of this hub.

Cautions in Brief

Full detail, including drug interactions and pregnancy, is on the Forms and Dosing page. The headlines:

• Never self-treat suspected malaria. Get a blood film or rapid diagnostic test and a supervised course of ACT. Do not use the herb as travel prophylaxis.
• Neurotoxicity in animals. High, repeated intramuscular doses of the oil-soluble derivatives arteether and artemether produced fatal brainstem damage in dogs and rats. Human studies at therapeutic doses, including formal auditory testing, have not reproduced this — but it is why nobody should improvise high daily doses for months.
• Pregnancy. Artemisinins are embryotoxic in early-pregnancy animal studies. Avoid the herb entirely in pregnancy, especially the first trimester, and while trying to conceive. (Large observational human data are more reassuring than the animal work, which is why WHO permits ACT in the first trimester when malaria is present — treating malaria in pregnancy is itself life-saving. That is a clinician’s decision, not a supplement decision.)
• Liver. Case reports link artemisinin supplements to cholestatic liver injury, including one case with intrahepatic ductopenia. Stop and seek care for dark urine, pale stools, right-upper-abdominal pain or jaundice.
• Asteraceae cross-reactivity. Artemisia pollen is a major allergen that cross-reacts with mugwort, ragweed and other composites. If you react to that family, expect trouble.
• CYP interactions. Artemisinin induces CYP2B6 and CYP3A4 (and autoinduces its own clearance), while whole dried-leaf extracts can inhibit the same enzymes. Either direction can move the blood level of a prescription drug.

Key Research Papers

Every identifier below was checked live against NCBI E-utilities — first author, title, journal and year all had to match before a PMID was printed. Where a claim could not be tied to a confirmed paper, a PubMed topic search appears instead of a number that might point somewhere else.

Discovery and mechanism

1. Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nature Medicine. 2011;17(10):1217–1220. Tu’s own account of Project 523 and the Ge Hong cold-water clue.
2. Tu Y. Artemisinin — a gift from traditional Chinese medicine to the world (Nobel Lecture). Angewandte Chemie International Edition. 2016;55(35):10210–10226.
3. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. International Journal for Parasitology. 2002;32(13):1655–1660.
4. Wang J, Zhang C, Chia WN, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nature Communications. 2015;6:10111. Heme activation damages hundreds of parasite proteins at once.

The drug: ACT and severe malaria

1. Dondorp A, Nosten F, Stepniewska K, Day N, White N; SEAQUAMAT group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. The Lancet. 2005;366(9487):717–725.
2. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. The Lancet. 2010;376(9753):1647–1657.
3. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. American Journal of Tropical Medicine and Hygiene. 2007;77(6 Suppl):181–192. Why a partner drug is not optional.
4. White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320(5874):330–334.

Resistance

1. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine. 2009;361(5):455–467. The first clear documentation, on the Thai–Cambodian border.
2. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine. 2014;371(5):411–423.
3. Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50–55. The kelch13 gene.
4. Balikagala B, Fukuda N, Ikeda M, et al. Evidence of artemisinin-resistant malaria in Africa. New England Journal of Medicine. 2021;385(13):1163–1171. Northern Uganda.

The herb itself — what it delivers, and the retracted trials

1. Räth K, Taxis K, Walz G, Gleiter CH, Li SM, Heide L. Pharmacokinetic study of artemisinin after oral intake of a traditional preparation of Artemisia annua L. (annual wormwood). American Journal of Tropical Medicine and Hygiene. 2004;70(2):128–132. One litre from 9 g of leaf = 94.5 mg artemisinin, about 19% of a recommended daily dose.
2. Blanke CH, Naisabha GB, Balema MB, Mbaruku GM, Heide L, Müller MS. Herba Artemisiae annuae tea preparation compared to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in adults: a randomized double-blind clinical trial. Tropical Doctor. 2008;38(2):113–116. Day-28 cure: 1 of 9 on tea.
3. Retracted. Munyangi J, Cornet-Vernet L, Idumbo M, et al. Artemisia annua and Artemisia afra tea infusions vs. artesunate-amodiaquine (ASAQ) in treating Plasmodium falciparum malaria in a large scale, double blind, randomized clinical trial. Phytomedicine. 2019;57:49–56 — retraction notice, 2020;78:153304.
4. Retracted. Munyangi J, Cornet-Vernet L, Idumbo M, et al. Effect of Artemisia annua and Artemisia afra tea infusions on schistosomiasis in a large clinical trial. Phytomedicine. 2018;51:233–240 — retraction notice, 2020;78:153303.
5. Argemi X, Houze S, Noel H, Broca O, Chidiac C, Rapp C. Imported Plasmodium falciparum malaria following non-pharmaceutical forms of Artemisia annua prophylaxis. Journal of Travel Medicine. 2019;26(8):taz073. Real people, real falciparum malaria.
6. de Ridder S, van der Kooy F, Verpoorte R. Artemisia annua as a self-reliant treatment for malaria in developing countries. Journal of Ethnopharmacology. 2008;120(3):302–314. A fair-minded review of the idea and its dosing and resistance pitfalls.

Beyond malaria

1. Pérez del Villar L, Burguillo FJ, López-Abán J, Muro A. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One. 2012;7(9):e45867.
2. Loo CS, Lam NS, Yu D, Su XZ, Lu F. Artemisinin and its derivatives in treating protozoan infections beyond malaria. Pharmacological Research. 2017;117:192–217.
3. Stebbings S, Beattie E, McNamara D, Hunt S. A pilot randomized, placebo-controlled clinical trial to investigate the efficacy and safety of an extract of Artemisia annua administered over 12 weeks, for managing pain, stiffness, and functional limitation associated with osteoarthritis of the hip and knee. Clinical Rheumatology. 2016;35(7):1829–1836. 42 people, three arms; the higher dose did nothing.
4. Krishna S, Ganapathi S, Ster IC, et al. A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine. 2015;2(1):82–90. The primary apoptosis endpoint was not met.
5. Efferth T. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. Seminars in Cancer Biology. 2017;46:65–83. A thorough review of a still-preclinical field.
6. Qiu F, Liu H, Duan Y, et al. Immunoregulation by artemisinin and its derivatives: a new role for old antimalarial drugs. Frontiers in Immunology. 2021;12:751772.

Safety

1. Brewer TG, Peggins JO, Grate SJ, et al. Neurotoxicity in animals due to arteether and artemether. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1994;88 Suppl 1:S33–S36.
2. Toovey S. Are currently deployed artemisinins neurotoxic? Toxicology Letters. 2006;166(2):95–104. The reassuring human counterweight.
3. Clark RL. Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reproductive Toxicology. 2009;28(3):285–296.
4. Saito M, Mansoor R, Wilairisak K, et al. Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis. The Lancet. 2023;401(10371):118–130.
5. Ruperti-Repilado FJ, Haefliger S, Rehm S, et al. Danger of herbal tea: a case of acute cholestatic hepatitis due to Artemisia annua tea. Frontiers in Medicine. 2019;6:221.
6. Svensson US, Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. British Journal of Clinical Pharmacology. 1999;48(4):528–535.

Live PubMed Searches

1. Artemisia annua
2. Artemisinin combination therapy
3. Artemisinin resistance and kelch13
4. Artemisia annua tea and malaria
5. Artesunate and schistosomiasis
6. Artemisinin and inflammation
7. Artesunate cancer trials
8. Artemisinin and pregnancy safety
9. Artemisinin and liver injury
10. Artemisinin and CYP2B6

External Resources

• WHO — artemisinin resistance questions and answers
• WHO Global Malaria Programme — treatment guidelines and reports
• CDC — malaria diagnosis, treatment and travel prophylaxis
• Nobel Prize — Tu Youyou, 2015 Physiology or Medicine
• PubChem — artemisinin compound record
• LiverTox — NIH database of drug and herbal liver injury
• ClinicalTrials.gov — registered artemisinin trials
• NCCIH — Herbs at a Glance

Connections

• All Herbs
• Artemisia annua (Sweet Wormwood) — the main topic page
• Artemisinin and Malaria
• Antiparasitic Uses
• Inflammation and Immune
• Forms, Dosing, and the Herb vs Drug Question
• Malaria — diagnosis, severe-disease warning signs, and the ACT regimens
• Wormwood (Artemisia absinthium) — the bitter, thujone-containing cousin
• Mugwort (Artemisia vulgaris) — the moxibustion herb, and a major allergen
• Andrographis — another intensely bitter herb with real pharmacology and inflated claims

Back to Table of Contents